close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

20.75 +7.06 (+51.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces $65 Million Private Placement
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Reports Third Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Second Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. (NASDAQ:PLSE) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 06/03/2022 -- Certain directors of Pulse Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Reports First Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
PULSE BIOSCIENCES (PLSE) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Pulse Biosciences, Inc. for Potential Securities Fraud Violations and Breaches of Fiduciary Duty
From Andrews & Springer LLC
Via Business Wire
News headline image
Final Deadline Reminder: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline Today: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
PULSE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Pulse Biosciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc. (PLSE)
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today